Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Polymeric Micelles in Taxane-Resistant Advanced Cancers
NCT06199895Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of Paclitaxel Micelles for Injection in pancreatic adenocarcinoma (PDAC), cholangiocarcinoma (CCA), lung cancer, gastric cancer (GC), esophageal carcinoma. Started Nov 2023; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)lung cancergastric cancer (GC)esophageal carcinoma
Beyond the preview
Go deeper on NCT06199895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199895.